Aclarion, Inc. announced its participation in the 38th Annual ROTH Conference scheduled for March 22-24, 2026, in Dana Point, California. The commercial-stage healthcare technology company, trading on Nasdaq under symbols ACON and ACONW, will use the conference to engage with institutional investors and analysts about its progress and future catalysts.
CEO Brent Ness will conduct one-on-one meetings during the event to discuss the company's advancement of Nociscan, its proprietary magnetic resonance spectroscopy platform. Nociscan is designed to help physicians identify painful discs in patients suffering from chronic low back pain by leveraging biomarkers and proprietary augmented intelligence algorithms. The technology represents a significant development in pain diagnostics, offering a noninvasive method to distinguish between painful and nonpainful discs in the lumbar spine.
"We look forward to engaging with the investment community at ROTH to share the progress we are making and the important catalysts ahead for Aclarion," stated Ness. "With a strong balance sheet, no debt, and a focused strategy to expand adoption of Nociscan in both the UK and US, we believe we are well positioned to execute on the significant opportunity ahead."
The company's technology works through a cloud-based SaaS platform that receives MRS data from MRI machines. Proprietary signal processing techniques extract and quantify chemical biomarkers associated with disc pain, which are then analyzed by AI algorithms to indicate potential pain sources. This approach provides physicians with critical insights to optimize treatment strategies for chronic low back pain, a condition affecting millions worldwide and representing a substantial market opportunity.
For business and technology leaders, Aclarion's participation in the ROTH Conference signals the growing intersection of healthcare technology, artificial intelligence, and diagnostic innovation. The company's focus on chronic pain management addresses a significant healthcare challenge while demonstrating how AI applications can create tangible clinical value. More information about the company is available at https://www.aclarion.com.
The announcement comes as Aclarion continues to advance its clinical and commercial activities. The company has indicated that an initial interim data readout from its ongoing clinical trial is expected to be internally available at the end of the third quarter, potentially serving as a significant catalyst for the technology's validation and adoption. For investors and industry observers, Aclarion's strong balance sheet and debt-free position provide financial stability as it pursues expansion in key markets.
Chronic low back pain represents a substantial burden on healthcare systems and patients globally, with traditional diagnostic methods often failing to pinpoint precise pain sources. Aclarion's technology addresses this gap by providing objective, data-driven insights that could lead to more targeted and effective treatments. The company's approach exemplifies how AI and advanced analytics are transforming medical diagnostics, potentially reducing unnecessary procedures and improving patient outcomes.
As healthcare continues to evolve toward more personalized and precise medicine, technologies like Nociscan demonstrate the practical application of AI in clinical settings. The platform's cloud-based architecture and SaaS model also reflect broader trends in healthcare technology toward scalable, accessible solutions that can integrate with existing medical infrastructure.
